Table 2.

Epigenetically modifiable genes relevant to ovarian cancer resistance and sensitization to cisplatin/carboplatin

Resistance/sensitization	Genes
Cisplatin resistance	OXCT1[18], GPCR[19], TET1[20], MLH1[21-23], HOXA10, HOXA11[21,24], NAGA[25], UCHL1[26], BCL2L1[27], FANCF[28-30]
Cisplatin sensitization	FANCF[31], NAGA[25], CCDC69[32], UCHL1[26]
Carboplatin Resistance	TMEM88[33], DOK2[34,35], p57(Kip2)[36], Plk2[37], HERV-K[38], SFRP5[39], SLFN11[40], ASS1[41]

ASS1: argininosuccinate synthase 1; BCL2L1: BCL2 like 1; CCDC69: coiled-coil domain containing 69; DOK2: docking protein 2; FANCF: fanconi anemia complementation group F; GPCR: protein coupled receptor; HOXA: homeobox A cluster; HERV-K: for HERV-K: human endogenous retrovirus type K; MLH1: mutL homolog 1; NAGA: N-acetylgalactosaminidase; OXCT1: 3-oxoacid CoA-transferase 1; Plk2: polo like kinase 2; SFRP5: secreted frizzled-related protein 5; SLFN11: schlafen family member 11; TET1: tet methylcytosine dioxygenase 1; TMEM88: transmembrane protein 88; UCHL1: ubiquitin C-terminal hydrolase L1